fluticasone and Lipodystrophy

fluticasone has been researched along with Lipodystrophy* in 1 studies

Other Studies

1 other study(ies) available for fluticasone and Lipodystrophy

Article	Year
Exogenous cushing syndrome mimicking human immunodeficiency virus lipodystrophy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Sep-15, Volume: 35, Issue:6 A 45-year-old man infected with human immunodeficiency virus (HIV) developed abnormal fat accumulations that initially were believed to be caused by HIV lipodystrophy. Further clinical evaluation revealed, however, that the patient had developed exogenous Cushing syndrome, which presumably was caused by the inhibition of CYP3A4's metabolism of inhaled fluticasone by the protease inhibitor ritonavir. Clinicians should be aware that clinical clues may indicate conditions other than lipodystrophy that may cause abnormal fat accumulation and that fluticasone should be cautiously administered to patients who are receiving ritonavir. Topics: Androstadienes; Cushing Syndrome; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Fluticasone; HIV; HIV Protease Inhibitors; Humans; Lipodystrophy; Male; Middle Aged; Mixed Function Oxygenases; Ritonavir	2002

Article

Year

Exogenous cushing syndrome mimicking human immunodeficiency virus lipodystrophy.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Sep-15, Volume: 35, Issue:6

A 45-year-old man infected with human immunodeficiency virus (HIV) developed abnormal fat accumulations that initially were believed to be caused by HIV lipodystrophy. Further clinical evaluation revealed, however, that the patient had developed exogenous Cushing syndrome, which presumably was caused by the inhibition of CYP3A4's metabolism of inhaled fluticasone by the protease inhibitor ritonavir. Clinicians should be aware that clinical clues may indicate conditions other than lipodystrophy that may cause abnormal fat accumulation and that fluticasone should be cautiously administered to patients who are receiving ritonavir.

Topics: Androstadienes; Cushing Syndrome; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Fluticasone; HIV; HIV Protease Inhibitors; Humans; Lipodystrophy; Male; Middle Aged; Mixed Function Oxygenases; Ritonavir

2002